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Abstract  
Obsessive-compulsive disorder (OCD) is common, emerges early in life and tends to run a chronic, 
impairing course. Despite the availability of effective treatments, the duration of untreated illness (DUI) 
is high (up to around 10 years in adults) and is associated with considerable suffering for the individual 
and their families. This consensus statement represents the views of an international group of expert 
clinicians, including child and adult psychiatrists, psychologists and neuroscientists, working both in high 
and low and middle income countries, as well as those with the experience of living with OCD. The 
statement draws together evidence from epidemiological, clinical, health economic and brain imaging 
studies documenting the negative impact associated with treatment delay on clinical outcomes, and 
supporting the importance of early clinical intervention. It draws parallels between OCD and other 
disorders for which early intervention is recognized as beneficial, such as psychotic disorders and autism 
spectrum disorders, as well as impulsive-compulsive disorders associated with problematic usage of the 
Internet, for which early intervention may prevent the development of later addictive disorders. It also 
generates new heuristics for exploring the brain-based mechanisms moderating the ‘toxic’ effect of an 
extended DUI in OCD. The statement concludes that there is a global unmet need for early intervention 
services for OC related disorders to reduce the unnecessary suffering and costly disability associated 
with under-treatment.  New clinical staging models for OCD that may be used to facilitate primary, 
secondary and tertiary prevention within this context are proposed. 
Key words 
obsessive; compulsive; OCD; early intervention; duration of untreated illness; staging 
 
 
Vignette  
I first had OCD symptoms when I was 17. Intensely worried and not daring to speak to anyone about my 
disturbing intrusive thoughts, I hesitated and then went to see a psychologist for help. Unfortunately, she 
failed to discuss the diagnosis of OCD with me and put me through an extensive program of Freudian 
psychoanalysis, which only made me worse.  
The OCD waxed and waned for several years, until I had a major relapse around the birth of my second 
son, when I was 30. This time, a friend lent me a book, which led me to a self-diagnosis of OCD.   
I immediately went to my GP, who agreed with my diagnosis. But with waiting lists too long for talking 
therapies, I went private. I saw a specialist in cognitive behavioral therapy (CBT) who took me through a 
program of exposure and response prevention that eventually helped me overcome that particular 
relapse.  
I’ve had many relapses since then, sometimes with crippling depression that has left me suicidal. 
Medications – particularly clomipramine – have helped with the depression, while subsequent courses of 
CBT have helped me manage my OCD. 
Had I got a correct diagnosis and treatment from the start, I’m convinced my subsequent relapses 
wouldn’t have been as bad. That’s why I believe that early diagnosis and treatment are key. 
 
 
 
 
 
Introduction  
Obsessive-compulsive disorder (OCD) represents one of the most common, chronic, costly and 
burdensome brain disorders, in terms of the personal impact, direct treatment-related costs and the 
indirect costs related to lost productivity (Hollander et al 2016). Commonly emerging in childhood or 
adolescence (Dell’Osso et al., 2016a), the disorder is associated with substantial distress, treatment-
seeking activity, functional disability and suicidality (Carmi et al., 2019). Evidence-based treatments 
include cognitive behaviour therapy (CBT) and pharmacological treatment with serotonin reuptake 
inhibitors (Skapinakis et al., 2016a). In cases where family accommodation of symptoms appears 
problematic, specific involvement of family members in the treatment plan can be helpful. Although 
studies suggest that recovery can be a realistic goal for a subgroup of the OCD population (Burchi et al., 
2018), ‘real world’ clinical outcomes are often disappointing. Relapse rates are high and fewer than 40% 
of treatment-seeking adults with OCD are reported to achieve a sustained remission when followed up 
long-term (Eisen et al., 2013, Skoog G and Skoog I, 1999). In a thirty years follow-up study of largely non-
treatment seeking cases of obsessive-compulsive disorders and syndromes, the median duration of OCD 
was 16y, roughly one-third of OCD cases did not remit and a poorer prognosis for remission was seen in 
those with more severe or longer duration of illness, psychiatric comorbidity and those seeking 
professional help (Fineberg et al 2013c)).   
 
OCD in childhood clinical samples also shows high rates of persistence despite treatment provision 
(Stewart et al., 2004; Zellmann et al., 2009). In the meta-analysis of childhood studies by Stewart and 
colleagues (2004), the pooled mean persistence rates were 41% for full OCD and 60% for full or 
subthreshold OCD. Epidemiological studies also suggest moderate stability of OC symptoms in children, 
with genetic as well as environmental factors contributing to persistence and remission (van Grootheest 
et al., 2007). In the study of Mancebo and colleagues (2014), a shorter latency to initiation of OCD 
treatment was associated with faster onset of remission.  Indeed, converging evidence from multiple 
centres indicates that a longer duration of untreated OCD (as opposed to an early onset of illness) is 
associated with increased clinical comorbidity and functional disability, as well as significantly poorer 
treatment-related clinical outcomes including treatment response and remission (Dell’ Osso et al., 
2013a; 2016a, Albert et al., 2018a (in submission), b; Rufer et al., 2005).  
 
Most cases of OCD arise before the age of 18y (Fineberg et al., 2013, Ruscio et al., 2010, Rapoport et al., 
2000, Dell’Osso et al., 2016a), and the duration of untreated illness (DUI) for OCD remains one of the 
highest for any severe mental disorder (Altamura et al., 2010). Most adults with OCD have been 
suffering for more than 10 years before effective treatment is initiated (Garcia-Soriano et al., 2014, 
Albert et al., 2018a). In the case of children and adolescents, the diagnosis is also often missed 
(Rapoport et al., 2000), and the lag between the onset of OCD and ascertainment of the diagnosis is 
reported by some specialized centres to lie at two to three years (Geller et al., 2000). The average DUI 
also exceeds two to three years (Walitza et al., 2008; Zellmann et al., 2009). This is a relatively long 
delay, given that the average patient age in these samples was only 13 years.  
 
Brain imaging has identified neuro-circuitry abnormalities associated with OCD appearing to evolve as 
transition from childhood to adulthood occurs.  In children and adolescents with OCD, similar altered 
functional activations in the same brain regions of affective and cognitive cortico-striatal-thalamic (CST) 
circuits exist as in adult OCD patients (Brem et al., 2012). However, a large mega- and meta-analysis of 
imaging data from multiple sites found that the brain alterations became more heterogeneous and 
complex with increasing age, suggesting that OCD is underpinned by complex, nonlinear 
neurodevelopmental mechanisms (Boedhoe et al., 2018, Boedhoe et al., 2017). Arguably, early 
intervention, bringing with it the potential for improved symptom-control, could help to interrupt the 
progression of such brain-based changes, though as yet we do not have imaging data to support this.    
 
By missing out on timely, effective treatment, the majority of people with OCD can be expected to 
endure many years of chronic or relapsing illness. Intervention aimed at delivering early accurate 
detection and diagnosis accompanied by targeted evidence-based interventions, could be expected to 
produce more clinically and cost effective outcomes (Brakoulias et al., 2018). Using similar arguments, 
early intervention teams for psychosis are well-established in America, Europe and Australasia (Edwards 
et al., 2002, NICE UK https://www.england.nhs.uk/mentalhealth/wp-content/uploads/.../eip-
guidance.pdf)).  
 
This consensus statement, representing the views of an international group of expert clinicians, 
scientists and people with lived experience of OCD, draws together evidence suggesting that greater 
emphasis on targeted early intervention, appropriately delivered within mental health services, is also 
required for people suffering with OCD. We propose new staging models for OCD, including prototypical 
criteria for early prodromal stages of the illness, as one of the first steps toward the development of 
early intervention strategies. We hope this statement will have a positive influence on clinicians’ 
practice. We note, for example, results of a survey among Danish clinicians suggesting that clinical 
recommendations on assessment and treatment for children and adolescents with OCD could be 
translated into positive clinical outcomes (Nissen and Thomsen, 2008).  
 
Methods  
In developing this consensus statement, a working group was selected from among the members of the 
European College of Neuropsychopharmacology (ECNP) Obsessive Compulsive and Related Disorders 
Research Network (OCRN), the International College of Obsessive Compulsive Spectrum Disorders 
(ICOCS) and the World Psychiatric Association Anxiety and Obsessive Compulsive Disorders Section. The 
group comprised expert clinicians, including child and adult psychiatrists, psychologists and 
neuroscientists, including those working in high, low and middle income countries, and included an 
individual with the experience of living with OCD. The group performed a narrative review of the 
scientific literature pertaining to the cost and burden of OCD across the lifespan, the duration of 
untreated illness (DUI) and its impact on health and wellbeing outcomes, and the potential role of early 
intervention, from various perspectives reflecting their experience and expertise.  After several 
iterations, a draft was circulated among the extended membership of the aforementioned organisations 
and further comments were integrated.  A final document was presented, discussed and provisionally 
endorsed, subject to minor amendments, by around 40 delegates in a symposium programmed within 
the 14thAnnual Scientific Meeting of the ICOCS, held in association with the ECNP OCRN, Barcelona, 
October 10th 2018.  
 
Epidemiology of OCD 
OCD has an estimated lifetime prevalence of 2 – 3% under DSM-III, DSM-III-R and DSM-V criteria (Robins 
et al., 1984; Weissman et al., 1994, Ruscio et al., 2010). Some epidemiological surveys of US and 
European citizens, using diagnostic instruments aligned with the DSM-IV, produced more conservative 
estimates of lifetime prevalence of respectively 1.6% (Kessler et al., 2005a) and 0.8% (Wittchen et al., 
2011). Another epidemiological survey (Kessler et al., 2011), possibly capturing a broader spectrum of 
cases, estimated the lifetime prevalence at 5.8% and 6.2% in low and high income countries 
respectively. Indeed, other epidemiological  surveys have estimated the prevalence of subclinical OC 
syndromes at between 7 – 25% (Bebbington et al., 1998, Fullana et al., 2009; Fullana et al., 2010; 
Fineberg et al., 2013a). Fullana and colleagues (2009) analysed the 20-year prospective Dunedin study of 
an unselected birth-cohort aged 11 to 32 years. Consistent with the US National Comorbidity data 
(Ruscio et al., 2010), DSM-IV OCD was reported in 2.3% of the sample at age 26 years and 1.8% at age 32 
years, whereas sub-syndromal obsessions and compulsions, affecting up to 25% of the cohort, were also 
found to be associated with significant impairment and help-seeking behaviour.  
Obsessions and compulsions often have their roots in childhood and, if persistent, are associated with 
psychosocial impairment (Fullana et al., 2009) including interference, risk of comorbidity and help-
seeking, irrespective of whether or not the diagnostic threshold for OCD is met. According to a UK 
survey of children and adolescents (Heyman et al., 2001), OCD was rare in younger children and 
increased towards adult rates, around 2%, by puberty. Moreover, the presence of obsessive-compulsive 
(OC) symptoms at 11 years predicted a high risk of OCD and more severe symptomatology in adulthood. 
Thus, sub-syndromal OC symptoms are common, associated with distress or impairment, may presage 
the onset of OCD and therefore represent a potential target for intervention.  
The most common age at onset of OCD was historically reported to occur around 20 – 30 years (Pollitt 
1957; Ruscio et al., 2010, Altamura et al., 2010). However, there appear to be two peaks of incidence, 
one with a pre-adolescent onset (mean age 9-10 ±2.5 years, Geller et al.,1998;  mean age 11 years, 
Taylor, 2011), and another in early adulthood (mean age 23 years, Taylor, 2011). Approximately three-
quarters of cases (76%) included in a meta-analysis demonstrated an early onset of OCD (Taylor, 2011). 
Other studies report an infrequent onset after 30 years (Grant et al., 2007). In a thirty year prospective 
epidemiological study (Fineberg et al., 2013a), although full OCD could not be identified before 10 years 
of age, sub-threshold cases were retrospectively reported as early as two years of age, around two 
thirds of OCD cases had emerged by the age of 22 years, and no new cases of OCD developed after age 
37 years. There was a clear increase in professional treatment related to OC severity. Lesser OC 
symptomatology tended to show an earlier age of onset than OCD, and OCD was frequently preceded by 
sub-diagnostic OC-symptoms. Suicidality and serious workplace problems were substantially associated 
with OC symptomatology, notably with OCD (OR = 4.10 and 4.61 for suicidality and workplace problems, 
respectively). However, similar to the childhood data (Fullana et al., 2009), those with lesser OC 
symptomatology, comprising 20% of the community sample, also reported significant suffering.  
 
Whereas OCD is over-represented in females in community studies (around 1.5:1), males are over-
represented in those with early onset of illness (Fineberg et al., 2013a). Evidence from studies on 
convenience  samples suggests that early onset OCD is associated with a number of distinguishing 
features, of relevance for clinical intervention, including comorbidity with neurodevelopmental 
disorders such as tic disorder and attention deficit hyperactivity disorder (ADHD)  and familial clustering 
suggesting a greater genetic contribution (Walitza et al., 2008, Walitza et al., 2010, Taylor 2011). Indeed, 
in some studies, early-onset OCD has been associated with specific gene variants of serotonergic, 
dopaminergic and glutamatergic receptors and synaptic brain related genes, neurotrophic and 
transcription factors (Walitza et al., 2014, Grünblatt et al., 2017). Symmetry, ordering and sexual or 
religious symptoms are also associated with early-onset OCD (Labad et al., 2008), possibly linked to 
comorbidity with tic disorders and tic-specific symptoms. Later onset cases include females developing 
OCD in pregnancy, after parturition or miscarriage, where the diagnosis is often missed (Williams and 
Koran, 1997). Prospective studies in postpartum females have shown an incidence of OCD ranging from 
4% to 11%, with some evidence suggesting avoidant and obsessive-compulsive personality traits 
predicted postpartum risk (House et al., 2016). Thus, early onset and later onset OCD seem to be 
distinguishable in terms of gender, comorbidity and genetics, and this may be of relevance for planning 
therapeutic intervention. 
 
The burden and costs of untreated OCD  
When making medical and policy decisions, including the introduction of early interventions and services, 
the burden of a disorder in terms of mortality, comorbidity, disability and effects on the quality of life, as 
well as the cost of interventions and their effectiveness, are of paramount importance. Although health 
economic studies in OCD are still limited, some data are available, helping to shed light on this matter.  
 
 
A strong consensus of scientific opinion emphasizes the negative impact of OCD on the quality of life, 
wellbeing and global functioning of affected patients and their related caregivers (Macy et al., 2013). A 
number of studies have examined quality of life (QoL) in OCD and several comprehensive reviews have 
been carried out (Coluccia et al., 2016; Macy et al., 2013; Subramaniam et al., 2013; among others). 
Patients with OCD show a poorer QoL than healthy controls and the population in general. Further, when 
OCD has been compared with other mental or physical conditions, some studies, although not all, have 
found that the effects of OCD on QoL are similar to those of serious mental illnesses such as schizophrenia 
(Macy et al., 2013; Subramaniam et al., 2013). The QoL domains most affected in OCD include social 
relationships, including emotional and psychological components. Physical domains, although impaired, 
are usually less affected.  
 Two key factors reported to influence QoL in OCD include disease severity and comorbidity. The 
association between OCD severity and QoL impairment is seen to affect even subclinical samples (Fullana 
et al., 2009, Fineberg et al., 2013a). Comorbid conditions, such as anxiety disorders, mood disorders or 
OC related disorders (OCRDs), which are very frequent in OCD patients, have a highly significant impact 
on lowering QoL. Importantly, treatment studies have shown that improvement in OCD is associated with 
an increase in QoL. Hollander and colleagues (2010) showed that disability and QoL significantly improved 
in patients showing a positive symptomatic treatment-response, and was significantly better compared 
to non-responders or those who experienced a relapse. Therefore, OCD, even at subclinical levels, involves 
a substantial decrease in QoL, which significantly improves with effective treatment and improvement of 
the condition. 
 
Studies focusing on disability have also demonstrated the substantial impact of OCD. Wittchen and 
colleagues (2011) examined the disability adjusted life years lost (DALY) associated with a broad range of 
mental and neurological illnesses in Europe. Although the study reported a lower prevalence of OCD 
(0.7%) than is usually reported in epidemiological studies, OCD accounted for 329,684 DALYs, which 
means a rate of 7.9 DALYs per 10,000 persons, i.e. higher than that reported in epilepsy (6.9), although 
lower than that of unipolar depression (10.3), which showed the highest disability. Indeed, the high rates 
of comorbidity usually existing between OCD and depression suggests that those with both conditions, 
who may show even higher levels of disability than those with ‘pure’ illness, might have been included in 
the depression group only, thus underestimating the true impact of OCD. Rates of under-employment 
ranging from 22% to as high as 38% have been reported among OCD subjects in community and clinical 
samples (Mancebo et al., 2008). Early intervention could thus be expected to reduce burden and costs of 
OCD, for example, by treating frequently co-occurring depression early. 
 
Although research into the costs of treated and untreated OCD is scarce, the existing data emphasise the 
significant indirect costs of OCD, such as loss of employment productivity, and the highly cost-effective 
impact of effective treatment (Hollander et al., 2016). For example, historical data estimating the 1990 
total costs of OCD in the USA found that indirect costs, reflecting lost productivity of individuals suffering 
from residual OCD, represented 74% of the total economic cost of OCD (Dupont et al., 1995). Another 
analysis by Knapp and colleagues (2002), which examined health service utilization, including mental 
health expenditure, inpatient hospitalization and ambulatory services, other formal care services, lost 
employment and education, family and caregiver impact, mortality, and transfer payments, concluded 
that the economic consequences of OCD were widespread, long lasting, and often profound, involving not 
only the direct costs of treatments and health services utilization, but also the indirect effects on personal 
income, the ability to work, productive contributions to the national economy and impoverishment of 
quality of life.  
 
Preliminary studies using health economic modelling have suggested that the treatment of OCD using 
standard pharmacological or psychological therapies, or their combination, is cost-effective. Two analyses 
(Skapinakis et al., 2016b, Fineberg et al., 2018) estimated that SSRIs represented the most cost-effective 
option, whereas the other (National Institute for Health and Clinical Excellence, 2006), estimated that the 
combined option was the most cost-effective. Further studies designed to test real-world effectiveness 
and cost-efficiency are indicated to confirm the relative cost effectiveness of all standard treatment 
modalities with greater certainty (Fineberg et al., 2018).  
 Duration of untreated illness in OCD  
Lack or delayed initiation of treatment are thought to play a relevant role in the overall burden of OCD. 
Over the past several years, research has investigated the DUI, defined, in most investigations, as the 
interval between the onset of a specific psychiatric disorder and the administration of the first 
pharmacological treatment at standard dosages and for an adequate period of time, in adherent 
subjects with OCD (Dell’Osso and Altamura, 2010).  
 
In those studies taking an epidemiological approach, the DUI in OCD has been consistently 
demonstrated to count among the longest for any psychiatric disorder - in recent years ranging between 
seven and ten years in adults (Altamura et al., 2010; Dell’Osso et al., 2013b; Poyraz et al., 2015, Albert et 
al., 2018a; Benatti et al., 2016), and exceeding two to three years in children (Walitza et al., 2008; 
Zellmann et al., 2009). These estimates are alarming, not only for the overall duration (in the case of 
children, constituting almost one quarter of their lifetime, assuming a median age of onset of 11 years), 
but also because in adults the DUI accounted for approximately half of the entire duration of OCD. This 
implies that patients spent half of their illness either untreated or receiving ineffective treatment 
(Viswanath et al., 2011; Dell’Osso et al., 2015, Poyraz et al., 2015). Another survey of child and 
adolescent referrals to a centre specialising in treating therapy-resistant OCD found that fewer than half 
of the referred patients (44.8%) had received adequate first-line treatment with CBT or SSRI before 
receiving care from this tertiary care center (Nair et al., 2014). Indeed, young people appear poor at 
accessing timely treatment and 'technical treatment failure' represents a common cause of apparent 
refractoriness (Micali et al., 2010). Importantly, the DUI in children and adolescents is reported to 
constitute one of the strongest predictors of OCD persistence over time (Micali et al., 2010). 
 A number of factors have been identified as contributing to the high DUI, including biological (genetic 
loading), familial/cultural (stigma-related attitudes), psychological (different illness phenotypes  and 
their relationship with secretiveness  (Viswanath et al., 2011, Dell’Osso et al., 2015, Benatti et al., 2016); 
believing that OCD symptoms do not represent illness (Poyraz et al., 2015)) and societal factors (poor 
access to psychiatric services with expertise in the diagnosis and management of OCD (Menchon et al., 
2016)). A recent Italian study showed a progressive, statistically significant reduction of the latency to 
first pharmacological treatment emerging across subsequent epochs of onset in patients with psychiatric 
disorders including OCD (Dell’Osso et al., 2016b). In other words, patients with a more recent versus a 
more distant onset of OCD waited less time before receiving a guideline-recommended treatment. 
Moreover, the shortening of the DUI was related to improved access to a psychiatrist, as opposed to the 
GP or another clinician, implying that if better access to appropriate clinical services, in particular to a 
psychiatrist, is provided, the DUI can be reduced. 
 
Specific clinical implications have been linked with a longer DUI. For instance, a DUI exceeding 24 
months was associated with a poorer response to pharmacological treatment (Dell’Osso et al., 2010, 
Albert et al 2018a (see below)). On the other hand, greater severity of OCD was associated with a 
shorter DUI (Dell’Osso et al., 2017), probably because, as has been demonstrated elsewhere (e.g. 
Fineberg et al., 2013a), those who are more severely unwell (and/or their caregivers) are more likely to 
seek help and receive treatment sooner, compared with those with a more chronic but fluctuant form of 
illness.  A longer DUI may also be associated with greater family accommodation of symptoms, thereby 
counteracting the goals of exposure and response prevention, promoting treatment resistance (Albert 
et al., 2017). Moreover, the effect of accommodating to OCD in a child or young person has a profoundly 
damaging effect on family relationships and the health of family members/caregivers (Peris et al., 2008).  
 
Another negative consequence of a long duration of untreated OCD is the development of a greater 
burden in terms of associated psychiatric or general medical conditions (Aguglia et al., 2018). Persistent 
avoidance of medical consultations associated with untreated fear of contamination, for example, may 
lead to failure to achieve appropriate diagnosis and treatment for medical problems (Albert et al., 2010), 
adding further burden to the existing psychiatric disorder. Anxiety and affective disorders are found to 
occur in over 60% cases (Ruscio et al., 2010). Psychiatric comorbidity is associated with increased 
severity and chronicity (Fineberg et al., 2013b) as well as higher levels of functional impairment, distress 
and suicidality (Angst et al., 2005). While different comorbid disorders impact variously on distress levels 
and psychosocial impairment, largely characterised in comorbid OCD by damage or a breakdown in close 
relationships, bipolar disorder, unipolar depression and alcohol misuse in OCD have additionally been 
associated with occupational role impairment and/or unemployment (Fineberg et al.,2013b). People 
with OCD and OC syndromes are also more likely to seek treatment if they suffer with a comorbid 
psychiatric disorder.  Severe, chronic illness is associated with high direct and indirect healthcare costs 
and high levels of hospitalisation (Drummond, 1993). Around 25% of these cases attempt suicide 
(Kamath et al., 2007).  
 
The epidemiological and clinical correlates of the DUI in OCD are of particular importance in the context 
of interventional strategies and services. DUI represents a modifiable factor, and intervention programs 
aimed at promoting early diagnosis, and bridging the gap between child and adult psychiatrists, are 
likely to reduce the latency to effective treatment (Dell’Osso et al., 2013c), and thereby reduce the costs 
and consequences of untreated illness. In addition, educative public-health programs aimed at 
promoting early OCD diagnosis should be disseminated to general practitioners and consideration given 
to translating scientific knowledge into information easily available for the general population, 
increasing the recognition of OCD by the lay public and primary care clinicians.  
 
Early Intervention Targets for OCD 
Despite the availability of effective treatments for OCD (Hirschtritt et al., 2017), the treatment gap 
(difference between individuals with OCD needing treatment and those actually receiving it) was 
estimated, in Europe, to stand at 25% of cases in 2004 (50% approximately in the world) (Kohn et al., 
2004). The proportion of subjects not being treated worldwide in more recent epidemiological studies 
was estimated to vary between 22 and 92%, with 38-to-90% of individuals not even seeking treatment or 
advice (Garcia-Soriano et al., 2014).  In those patients with OCD receiving treatment, the extended DUI 
can be attributed to long delays in actively seeking help (e.g. the mean interval between disorder onset 
and help seeking behavior has been quantified as approximately 7 years (Albert et al., 2018a)). Educational 
campaigns presenting OCD as an illness that can be cured and resources to improve access to mental 
health services could in the near future shorten the delay in seeking treatments. 
 
However, the interval between help seeking and receiving an adequate treatment for OCD is also 
significant (approximately 2 years for pharmacological treatment (Strengler et al., 2013; Albert et al. 
2018a)). This means that there is difficulty for physicians and/or mental health professionals in recognizing 
and diagnosing OCD appropriately (high rates of OCD symptom misidentification by mental health 
professionals were found (Glazier et al., 2013)), or in prescribing or offering an adequate treatment (it 
may be that psychological therapies other than CBT with exposure and response prevention are applied, 
or that antidepressants other than clomipramine or SSRIs are prescribed, or for less than the required 12 
weeks, or at sub-therapeutic doses). There is thus a strong need for early recognition and appropriate 
diagnosis for OCD. 
 
The importance of shortening the DUI becomes evident when examining treatment-response rates. In 
patients with OCD, response rates are significantly reduced when the DUI is longer, and this is even more 
evident when considering the first ever adequate treatment (e.g. from 70% to 40% for those with a DUI≤24 
months versus >24 months) (Dell’Osso et al., 2010; Albert et al., 2018a). This may imply that the longer 
the DUI the greater the “biological or psychosocial damage” associated with the duration of severe 
symptoms. It may be speculated that the DUI in OCD promotes neuroprogression or neurodegeneration, 
as hypothesized for psychosis (Anderson et al., 2014). Studies demonstrating an association between 
longer duration of OCD and either reduced hippocampal and amygdalar volumes (Atmaca et al., 2008) or 
reduced N-acetyl aspartate among other neurochemical measures in several cerebral areas (Gnanavel et 
al., 2014) provide some evidence in favor of a “neuroprogressive or neurodegenerative” hypothesis. 
Indeed, an as yet un-replicated study found that in those OCD patients who relapsed after discontinuation 
of drug, response rates were lower following re-instatement of the same pharmacological treatment 
(same compound given at exactly the same dosage) compared to the initial response rates.  These findings 
have been interpreted to suggest that relapse in OCD adversely affects treatment outcomes (Maina et al., 
2001). 
 
Early Intervention for Children and Adolescents with OCD  
It would seem obvious that any disorder, including OCD, deserves early intervention to alleviate 
suffering and abbreviate functional impairments associated with illness. However in youth, this is 
particularly crucial due to several specific factors.  
 
First, the unique cognitive, academic and social developmental tasks of childhood and adolescence are 
concentrated into a relatively few years. If these developmental milestones are disrupted, it may have 
lasting consequences well beyond childhood, and perhaps even a lifelong effect, with an altered 
educational, professional or social trajectory. Youth are therefore particularly vulnerable to the effects 
of mental illness, due to the cascading effects of functional impairments and in no other population 
does early intervention hold more promise for reducing chronicity, and the economic and social burdens 
associated with OCD.  In addition, children are frequently less able to articulate their obsessional 
thoughts or to have the maturity and ego-function to recognize their obsessional mental experiences as 
aberrant, as something different from normal self, so that insight may be lacking and obsessions can 
only be inferred by (adult) observers of ritualistic behaviour (Storch et al., 2014). 
 
Next are the illness-specific factors associated with OCD in youth that are not seen as frequently in 
adults and that may require specialist knowledge and intervention. These include symptom-specific 
presentations or symptom dimensions in young patients (Geller et al., 2001b, Stewart et al., 2007), a 
unique and developmentally-specific profile of common comorbid psychiatric disorders (Geller et al., 
2001b), a unique pattern of neurocognitive deficits (Geller et al., 2017), increased familial aggregation of 
early-onset OCD (Rosario-Campos et al., 2001, Walitza et al., 2010, Taylor, 2011), high rates of family 
accommodation as a consequence of children being embedded in family units and perhaps 
environmental or epigenetic influences that occur at a sensitive period of neural maturation (Geller et 
al., 2007). Recently it was shown that serotonin transporter- gene methylation levels were significantly 
higher in children and adolescents with OCD compared to controls and adult patients with OCD. 
Furthermore, morning awakening salivary cortisol levels positively correlated with methylation levels 
(Gruenblatt et al., 2018).  Together, these findings have led some to posit a developmental subtype of 
OCD affecting youth and this is partly reflected in the DSM-5 which specifies a tic-related form of OCD 
with early onset that is male predominant, with different patterns of familial inheritance, comorbidity 
and course (American Psychiatric Publishing, 2013). 
 
Obsessional anxiety frequently follows developmental themes that may be difficult to dissociate from 
normal childhood development (Geller et al., 2000). In childhood, evolving autonomy and separation 
often lead to fears of harm to attachment figures and may produce behaviours that mimic separation 
anxiety but are driven by OCD (Storch et al., 2011), while in adolescence, tensions around sexuality and 
moral and religious development frequently find their way into obsessional content (Geller et al., 2000).  
 
High rates of psychiatric comorbidity also present clinical challenges. More than half of children 
diagnosed with OCD will meet criteria for another psychiatric diagnosis, even in epidemiological 
samples, and rates as high as 80% are reported in clinically ascertained cohorts. In comorbid OCD, 
medication treatment approaches often diverge, producing a challenge from a psychopharmacological 
perspective, since OCD cannot be treated in isolation. Each comorbid disorder presents risk for longer-
term outcome in affected children (Walitza et al., 2008). Overlap with autism spectrum disorders (ASD) 
is common and can present diagnostic and treatment challenges particular to this age group that must 
necessarily include family and educational interventions (Volkmar et al., 2014). Clinical studies have also 
demonstrated comorbid impulse-control problems such as tic disorders and ADHD, occurring alongside 
anxiety symptoms, in subsets of children with OCD, co-segregating in families and often presenting a 
classical “triad” diagnostic picture (Geller et al., 2007). Impulse-control problems continue to feature in 
cases of adult OCD, while preclinical research has identified neuropsychological markers of inhibitory 
dyscontrol in OCD families (Chamberlain et al., 2005). Prospective studies, beginning in childhood, 
investigating the role of latent markers of the association between early-onset impulse-control disorders 
and OCD, may elucidate a specific OCD subtype (Kessler et al., 2011). A ‘baby sibs’ research programme 
for families with an existing  child with OCD, following-up at risk siblings from birth to identify early signs 
and biomarkers indicating a role for early intervention, represents a rational future step. 
 
Finally, treatment approaches and outcomes in childhood OCD appear to be somewhat varied, and 
possibly more optimistic, compared with those seen in adult patients. For example, family therapy 
techniques aimed at challenging the unhelpful accommodation of OCD symptoms may be particularly 
helpful in the younger age group (Peris et al., 2017). In a meta-analysis by Stewart and colleagues (2004) 
the persistence rate for full OCD was around 40% and for subthreshold OCD was around 60%. 
Randomized controlled pharmacological trials have been hampered by very high placebo response rates 
in children (Geller et al., 2003). Compared to medication, CBT in youth has undergone less controlled 
investigation versus psychological placebo (Skapinakis et al., 2016), but is acceptable to parents and 
seems particularly effective when delivered in systematized formats that include family participation 
(Peris et al ., 2017). Further, the recent Nordic long term treatment study (NordLOTS) (Hojgaard et al., 
2017) suggests that, with extended CBT protocols tailored to outcome, about two thirds of children will 
have good outcomes with response and remission. A further study found that when  children and 
adolescents were first randomized to SSRI or group CBT, followed by a second randomization to switch 
or add the other treatment for non-responders, significant improvement occurred over time in all 
groups, regardless of the sequence of treatments (Fatori et al., 2018). 
 
In summary, youth with OCD present particular challenges but also a hopeful outcome picture when 
early intervention can be applied in standardized way that can mitigate the prolonged harmful effects of 
untreated illness (Storch et al., 2018). No prospective controlled longitudinal study has examined 
whether effective early intervention reduces long-term disability from OCD (or impact on a child’s ability 
to meet developmental milestones). Although the question as to whether or not early intervention 
produces better outcomes ideally requires testing in a  prospective randomised controlled trial,  it is 
unlikely, for ethical reasons, that a study requiring adequate treatment to be withheld would ever be 
undertaken. Nevertheless, we judge many of the arguments supporting early intervention for OCD in 
childhood (alleviating suffering, optimising the navigation of critical developmental milestones, 
counteracting negative effects of family accommodation, better treatment outcomes compared to 
adulthood OCD)  to be  strong and strategies for early intervention should be incorporated into existing 
standards of care programmes (such as Menchon et al., 2016).  
 
Staging models for OCD 
“Illness staging” is a commonly used technique in several medical disciplines, helping to predict course 
or prognosis and optimize treatment (Berk et al., 2017).  Staging models in psychiatry have mainly been 
applied to schizophrenia, bipolar disorder and depression (de la Fuente-Tomas et al., 2018). Based on 
the proposition that psychopathology advances predictably, they propose an “at-risk” or latency stage, a 
prodromal stage with the odds of progressing to a first clinical threshold episode, and a full illness stage 
with the potential to revert or progress to late or end-stage manifestations.  Such models imply the 
presence of an active disease process that, if not remediated, leads to neuro-progression, a more 
damaging disease course and functional deterioration (Berk et al., 2017). Staging models also imply that 
stage-specific treatments may be successful in impeding illness progression as well as targeting 
symptom reduction. These treatment approaches range from ‘prevention’ for at-risk individuals, to early 
intervention approaches for prodromal and newly diagnosed individuals, complex combination therapy 
for recurrent or resistant illness, and palliative-type approaches for those with chronic, late stages of 
illness (Berk et al., 2017).  
 
A similar staging model could be proposed for OCD and other OCRDS. The utility and validity of such a 
model would depend on evidence linking the different stages to clinical outcome, treatment response 
and neurobiological measures.  A substantial proportion of the population (estimated at 21% and 28% in 
the studies by Ruscio et al., 2010 and Fineberg et al., 2013a) report subthreshold symptoms that may  
represent the first ‘at risk’ stage. These individuals do not meet the full diagnostic criteria for OCD, and 
in the main do not progress to full blown OCD, but do nevertheless experience some harms (Fullana et 
al., 2009, Fineberg et al 2013a). Conversely, cases of full-blown OCD are usually preceded (or followed 
by) sub-diagnostic OC-symptoms (Fineberg et al., 2013a). One study indicated that the earliest 
symptoms shown by OCD patients belong to the symmetry and ordering dimension (Kichuk et al., 2013). 
These symptoms may be of particular relevance for identifying those most at risk of developing OCD. 
Appropriate methods of clinical intervention for these cases remain a matter for further research, as 
traditional treatments (including SSRI, CBT) may not be appropriate. In the case of at risk children, as a 
general principle, it would seem wise to educate parents not to accommodate OC symptoms and how to 
avoid undue antagonism.   
 As described above, OCD develops in vulnerable cases, including those with prodromal OC symptoms, 
through the actions and interactions of specific inherited and environmental risk factors, such as family 
history of OCD, tic, or exposure to trauma or, in the case of young women, pregnancy and childbirth. 
Individuals with subthreshold OC symptoms or traits (especially symmetry, ordering) alongside exposure 
to these factors may therefore represent the second stage i.e. “ultra-high risk’ mental states, for whom 
early intervention in the form of careful monitoring to prevent progression to full blown OCD would be 
relevant. There are thus arguments to actively screen for OC symptoms and syndromes in appropriate 
high risk groups, such as within maternity services, focussing on ultra-high risk parents and children.  
 
OCD represents the next stage, manifesting usually in childhood as the first clinical episode and 
requiring intervention with evidence based treatments such as CBT and SSRI. Further stages of illness 
could be conceptualised as responsiveness or resistance to different interventions (CBT, SSRI, 
antipsychotic) staged according to evidence – based algorithms (e.g. Fineberg et al., 2015). 
 
The establishment of a staging model would generate testable hypotheses for onwards validation in 
longitudinal naturalistic trials, addressing gaps in knowledge e.g. the proportion of cases staged as 
medium or high risk eventually developing OCD and the predisposing or precipitating factors linked to 
transition to the full disorder, as well as interventional studies e.g. the effectiveness of low intensity CBT 
interventions in sub-syndromal groups in relieving distress or preventing conversion into OCD.  
 
Immunological Factors and Early Intervention 
The role of the immune system and inflammation in OCD pathophysiology emerged in the early nineties, 
when an autoimmune pathophysiology hypothesis was proposed for several case series of OCD 
characterized by pre-pubertal acute onset, episodic course and concurrent neurological abnormalities 
such as choreiform movements occurring or exacerbating after exposure to infection (Swedo et al., 
1998). This syndrome, initially termed pediatric autoimmune neuropsychiatric disorder associated with 
group A beta-hemolytic streptococcus (GABHS) (PANDAS), was renamed pediatric acute 
neuropsychiatric syndrome (PANS), since evidence highlighted the fact that several agents other than 
streptococcus might be involved (Chiarello et al., 2017). The mechanism hypothesized for PANS involves 
cross-reactivity between gangliosides in basal ganglia neurons with the GABHS and/or other agents’ 
cells, as is the case for the Sydenham’s chorea (Chiarello et al., 2017). Indeed, there are some reports of 
anti-basal ganglia antibodies in the serum of PANDAS/PANS cases (Pearlman et al., 2014). Also, evidence 
of inflammatory and immune system abnormalities in the form of higher rates of total monocytes and 
CD16+ monocytes were reported in pediatric OCD (Rodríguez et al., 2017).  
 
Inflammatory biomarkers are important, as they may identify a potentially remediable prodromal stage 
of early onset OCD. The relevance of neuro-inflammation and/or autoimmunity in OCD is not necessarily 
limited to subsets of pediatric and acute onset forms of OCD, and could be also relevant for adults. 
Indeed, recent studies showed the presence of inflammation in the cortico-striatal-thalamo-cortical 
circuit (Attwells et al., 2017) and the presence of greater plasma levels of IL-2, IL-4, IL-6, IL-10 and TNF-α 
levels in adult OCD patients compared to controls (Rao et al., 2015), as well as higher rates of anti-basal 
ganglia antibodies (Pearlman et al., 2014, Nicholson et al., 2012). Systemic autoimmune diseases are 
reported to be associated with an increased risk of OCD (Wang et al., 2018). Other recent evidence 
showed that the gut-microbiota may have a potential role in brain inflammation and PANDAS/PANS 
cases (Quagliarello et al., 2018). Thus, neuro-inflammation and autoimmunity seems to be involved in 
several forms of OCD, perhaps especially OCD related to tic or movement disorders (Orefici et al., 2016). 
An ongoing European longitudinal observational multicenter study is investigating the association of 
environmental (e.g. infectious agents) factors with the onset and course of tics and/or OC symptoms 
through the prospective observation of at-risk individuals (Schrag et al., 2018). Finally, a recent genome-
wide association study found genetic correlations between immune-related disorders and several 
psychiatric disorders, including OCD (Tylee et al., 2018). 
 
Although some studies demonstrated that OCD symptoms have improved with plasma exchange, 
intravenous immunoglobulin and antibiotic prophylaxis (e.g.  Snider et al., 2005), the use of antibiotics 
and immunoglobulins for early and acute onset OCD patients remains controversial (Burchi and Pallanti, 
2018; Williams et al., 2016).Additional evidence hints at a potential therapeutic role for anti-
inflammatory agents (Spartz et al., 2017). Interestingly, SSRIs (a first line OCD treatment) have been 
shown to exert several immunological effects, such as reduced lymphocyte proliferation, alteration of 
cytokine secretion and induction of apoptosis (Gobin et al., 2014).  
 
 
Therefore, when treating a patient presenting with early onset OCRD, clinicians should consider an 
assessment of inflammatory and immunological aspects, such as infective history, OCD symptom-course, 
inflammatory markers, familial history of autoimmunity and the gut-microbiota. Early recognition of 
inflammatory and immunological factors in early and acute onset OCD patients may represent a crucial 
starting point for appropriate intervention in this population and could potentially advance the field 
toward a putative etiological treatment of OCD.  
 
 
Monitoring and Early Prevention Via Remote Digital Assessment  
The extensive use of smartphones and vast amount of information they contain, has positioned cellular 
devices and technology as a rich database for behavioural and social activities (World Health 
Organization Report (2011)). Harnessing smartphone technology into the clinical field has introduced 
new, real time, data sources that hold promise in characterizing clinical functioning (The National 
Institute of Mental Health (2017)). Characterizing clinical populations based on such data sources, 
known as digital phenotyping, is a new way of  identifying individuals at risk, appropriately deploying 
interventions, and assessing their efficacy (Faurholt-Jepsen et al ., 2017). 
 
Clinical disorders characterized by heightened compulsivity (e.g. OCD , body dysmorphic disorder, 
gambling disorder, restricting anorexia nervosa), represent disorders for which the human-device 
interface can putatively represent a significant area of observed symptomatology. Applications like 
‘Instagram’ have issued health support platforms for their users, in response to acknowledging that 
mental health symptoms are linked with the use of its platform. PUI-related symptoms are prevalent in 
specific age groups of individuals with OCD (Ioannidis et al., 2018). While the concept of PUI is still under 
debate, and the direction of causation of the observed correlations is still contentious, there is 
anecdotal evidence that the online platforms facilitate a ‘millieu’ in which OCD symptoms flourish 
(Mazmanian et al., 2017).  
 Digital monitoring is most relevant in groups for whom there is a high risk of delayed or missed 
diagnosis, where health services compliance is low and symptoms are often concealed, such as 
adolescents and young adults. Therefore, there is an argument for the use of digital phenotyping, 
created using an anonymous monitoring app, downloaded by those in high risk groups. The resulting 
data would enrich clinical monitoring with an objective and continuous data source. Therefore, data 
mining methods are highly relevant for the early detection and diagnoses of OCRD, where compulsions 
may be performed using the human-device interface (online checking, taking photos, list making etc.) 
and can provide a unique digital signature, which can be statistically characterized. This may open a 
wide array of novel screening methods and digital instruments, which can boost early detection of 
OCRDs. Although self-report of OCRD symptoms has a generally acceptable reliability, such methods, 
have the propensity to source high dimensional 24h longitudinal data and enable the detection of covert 
symptoms which are otherwise hard to subjectively or objectively monitor, due to their nature (e.g. 
complex diurnal variation). Thus, several clinical situations characterizing OCRD could be better 
understood, and possibly prevented, by employing a digital personalized model capable of predicting 
when certain deviations from a patient’s usual behavior may lead, with high probability, to his or her 
health deterioration, or indicate that a deterioration has already occurred.  
 
During this informatics age, it is highly important that personal information is handled sensitively and 
the right to private life is respected in the digital space. Therefore, it is essential to highlight that a 
collection of personalized data of such nature, should be managed through rigorous processes and via 
secure mediums and databases, for which participants have given explicit consent. Researchers and 
clinicians setting up such processes would undertake this endeavour with grave ethical sincerity. Data 
collection of such magnitude and sensitivity would be acceptable, if it was completely anonymous. As 
such, techniques can be implemented by which devices could allow the sourcing of passive data sources 
(communication and diurnal variation patterns, social media and internet use, gyroscope movement, 
app usage, location information, word use and keyboard use), along with anonymous active data 
sources (voice prosody, facial and eye coding, linguistic analysis, remote survey). Computational 
approaches in machine learning (e.g. data mining) and artificial intelligence may then be used to derive 
clinical characterization and prediction based on these sources of big data, creating clinically valid 
screening and monitoring algorithms, which could be applied for early detection and intervention in high 
risk populations.   
 
Toward Primary, Secondary and Tertiary Prevention? 
In considering the development of early intervention strategies, it can be useful to conceptualise the 
‘prevention’ of OCD and OCRDs in terms of primary, secondary and tertiary prevention. Primary 
prevention involves the prevention of the development of OC symptoms. Secondary prevention refers 
to the early identification and treatment of individuals who develop OC symptoms to prevent 
progression to OCRDs. Evidence shows that patients continue to improve over time and those who stay 
longer under treatment tend to benefit more from it. Therefore, the earlier the patient starts getting 
treated, the more likely he/she will stay under treatment long enough to improve (Costa et al., 2017, 
Jakubovski et al., 2012, Diniz et al., 2011). Tertiary prevention aims to reduce the impact of the disorder 
and the level of disability once individuals have been diagnosed. However, the literature in relation to 
the prevention of OCRDs is sparse. 
 
A combination of genetic and environmental factors appear to be relevant to the aetiology of OCD, e.g. 
the observation that hoarding symptoms and contamination/cleaning symptoms are more likely to also 
be present in first-degree relatives (Brakoulias et al., 2016b, Zilhão  et al., 2018). These factors are 
thought to interact to precipitate OCD in individuals with subthreshold symptoms. Thus the primary 
prevention of OCD could involve strategies to prevent the genetic expression of OCD or modifying 
environmental factors that might contribute to the expression of OCD. As genetic strategies have not yet 
advanced to a stage of being used therapeutically (see above), we must currently look towards 
environmental factors. For 80% of people with OCD, their symptoms begins in childhood (Goodman et 
al., 1995), with the first peak of onset being reported around 11 years of age (Taylor, 2011). Early-life 
factors, including physical abuse, negative emotionality, perinatal insults, poor motor-development and 
personality or conduct problems have been reported to predict the incidence of OCD (Grisham et al., 
2011). Hence childhood environmental factors are a target area of investigation.  
 
Psychoeducation and the reduction of family accommodation, i.e. the act of parents, siblings or partners 
accommodating to the high-risk individual’s requests to comply with their compulsions, are promising 
areas for primary prevention, but have only been evaluated as secondary preventative measures with 
some evidence that CBT-based family intervention programmes improve treatment outcomes (Merlo et 
al., 2009). Thus, currently the impact of such programmes on the long term prognosis is unknown. 
 
, The advantages of anticipating treatment initiation through early intervention, so that patients can 
benefit from long-term improvement with treatment maintenance, requires evaluation in long term 
studies. Nevertheless,  it can be postulated that early intervention in childhood provides an opportunity 
to reduce symptoms and their impact on a child’s ability to meet developmental milestones (Freeman et 
al., 2007).The hypothesis that some OCRDs may be precipitated by neuro-immunological reactions has 
spurred several treatment studies. Although the generalisability of immune modulating interventions 
remains unclear, if OC symptoms are detected early, such treatments could be viewed as secondary 
prevention or early intervention. Biomarkers that might predict who will respond to these often costly 
and limited treatments are also required. 
 
Tertiary prevention has been limited by an inadequate number of trained clinicians to deliver evidence 
based treatments such as exposure and response prevention therapy (Brakoulias et al., 2016a). Tertiary 
prevention would also aim to reduce the significant comorbidity associated with OCD with 
approximately 75% having a co-occurring other anxiety disorder (Brakoulias et al., 2011) and higher 
rates of ADHD, tic disorders, major depression (Hasler et al., 2007) and suicide (Alonso et al., 2010, 
Maina et al., 2007, Kamath et al., 2007). Indeed, OCD was one of the most important predictors of 
lifetime comorbidity in the World Mental Health Surveys and, as an early-onset disorder, represents an 
important marker of youth at high risk for progression to later disorders (Kessler et al., 2011). The wider 
dissemination of clinical practice guidelines promoting evidence-based treatments (e.g. National 
Institute for Health and Clinical Excellence 2006, Menchon et al., 2017) could be seen to assist tertiary 
prevention. 
 
Early intervention in low and middle income countries  
The importance of developing early intervention programs for mental health problems in low and 
middle and low-income countries (LMIC) is obvious. First and foremost, as the majority of the world 
population resides in LMIC, most individuals with or “at risk” for OCRDs live in these regions. Secondly, 
most of the research on both OCRDs and early intervention has been performed in high-income 
countries (HIC), thus excluding individuals with different ethnic and sociocultural backgrounds (Durkin et 
al., 2015). It is therefore unclear how data from HIC samples apply to subjects from LMIC. Finally, the 
amount of resources that can be dedicated to early intervention for mental health problems (including 
OCRDs) is both lower than those from HIC and more likely to be affected by problems such as political 
instability, economic crisis, or even war, among others (Parra-Cardona et al., 2018). However, the 
concept of LMIC is also heterogeneous. For instance, countries with stronger economies, such as Brazil, 
Russia, India, China, and South Africa (collectively known as the BRICS) were able to establish an early 
intervention program for psychosis and to perform relevant research in OCRDs (e.g. Reddy et al., 2010). 
It is natural for them, therefore, to turn their attention to early intervention for OCRDs. 
 
There is now evidence from studies performed in some LMIC that DUI in OCD is similar to those in other 
parts of the world (Poyraz et al., 2015). For instance, a recent Brazilian study found that the mean DUI, 
calculated as the age at which patients were first seen by a mental health professional minus the age at 
onset of OCD, was almost eight years (Vigne et al., 2018). However, DUI in OCD may be shortened by 
other targeted enterprises. In 2003, seven Brazilian universities established The Brazilian Research 
Consortium for Obsessive-Compulsive Spectrum Disorders to strengthen and develop research on 
OCRDs across the country (Miguel et al., 2008).This initiative was made possible by significant 
investments of the Brazilian research funding agencies, which allowed training in OCRDs’ assessments 
across different centres, and also by the structure of the Brazilian health system itself, which is 
universal, comprehensive, decentralised, and free of charge in terms of service provision. These 
initiatives helped to establish Brazil as one of the research hubs in OCRDs and also to leverage 
assessment and treatment of OCRD across the country.  
 In this specific context, attempts to shorten DUI in OCRDs should probably involve greater contact 
between local mental health specialists and family physicians, one of the tenets of the Brazilian mental 
health system (Fagundes Junioret al., 2016). Nevertheless, if we consider the DUI as the delay between 
the awareness of the discomfort or interference in functioning caused by OCD symptoms - instead of 
OCD symptoms onset - and the initiation of OCD-specific treatment, the mean DUI is still substantially 
high (Miguel et al., 2008). Therefore, even in the context of universal access to public health services in 
LMIC such as Brazil, there is a significant delay to OCD-specific treatment initiation explained by factors 
that go beyond treatment availability. 
 
Integration  
OCD has a profound impact on the quality of life of the subject and involves a significant burden on the 
individual, the family and society. The consequences of OCD may be increased by the frequently 
associated comorbidities, such as depression or anxiety disorders. Individuals suffering with OCD that 
has either not been detected or not properly treated are likely to experience these consequences. The 
recognition that OCD occurs within an expanded diagnostic class of OCRDs, with a combined prevalence 
estimated at 9.1% (OCD + OCD related disease prevalence) (Carmi et al., 2019), implies that OCD and 
OCRD are affecting roughly one out of 11 of the general population.  
 
OCD frequently emerges in childhood and adolescence, and through the burden (which evolves) of the 
time and energy spent on the OCD, has the potential to (and often does) interfere with the achievement 
of social and occupational milestones. These secondary phenomena (lacking social occupational and 
interpersonal skills) add another degree of difficulty and resistance to treatment that could have been 
averted, had treatment started earlier. The same is true for secondary depression, which is common and 
very frequently presents another hurdle on the road to recovery  
 
The issue of DUI in OCD is different from other severe brain disorders, as it is quite likely that for many 
individuals there is the possibility to disguise the symptoms from family and friends for some 
considerable time. The ego – dystonic features (symptoms accepted as integral to the individual’s values 
and goals) and poor insight (unawareness that the obsession and / or compulsion is excessive or 
unreasonable) frequently seen in OCD may also deter individuals from coming forward. Moreover, as 
the symptoms are frequently territorial and narrowly focused (as opposed to depression, psychosis etc.), 
OCD is more likely to escalate under the “clinical radar” and consequently exerts an even bigger 
(unwanted) effect, not only on quality of life but also on psycho-social functioning.  
 
Due to the specific characteristics of OCD (ego-dystonic and territoriality) on the one hand and the 
tendency of the disorder to get worse over time (as opposed to the usually episodic course of MDD for 
example), OCD and OCRDs are conditions for which early detection is both challenging and critical. 
Another relevant point relates to the known “toxic effects” of the illness; longer duration is not only 
associated with increase in severity and burden, but also interfaces with other domains ranging from 
occupation to social life, parenting and personal relationship. As the impact on the quality of life 
worsens with the passage of time, the relevance and importance of early detection and intervention for 
these disorders appears obvious. 
 
We therefore recommend adoption and validation of a staging model for OCD, linked to primary, 
secondary, tertiary prevention, focussing on addressing environmental and biological etiological targets. 
As we do not as yet have evidence that, by addressing modifiable environmental risk factors such as 
parental rearing practices, the primary prevention of full-blown OCD in individuals thought to be at risk 
is possible, early intervention is likely to be of greater importance for clinicians and health services. This 
model has scope for application at a global level, including among LMIC.  Moreover, recent advances in 
information technology have the capacity to transform the way we approach early intervention and 
change the landscape in this regard.  
 
The emphasis on early detection rests upon the known clinical and cost effectiveness of currently 
available interventions (SRIs, ERP, family interventions)( National Institute for Health and Clinical 
Excellence 2006). By applying these treatments early, there is a real possibility of altering (positively) the 
trajectory of OCD and OCRD, to enable patients to free themselves from the prison of their symptoms 
and access the opportunity to fulfill their potential. This component i.e. the availability of effective 
therapeutic tools, gives early intervention for OCD clinical weight. “Had we done it, it would really have 
had significant clinical impact”.  
 
Thus, early detection and intervention strategies could be expected to prevent chronic evolution, are 
likely to be cost-effective and to improve the quality of life and reduce the overall burden of illness. 
Achievable objectives include reliable identification of ‘at risk’ and established cases of OCD e.g. based 
on family history, phenotype and significant life events such as pregnancy and childbirth, alongside 
timely diagnosis and improved access to clinicians and services capable of providing targeted 
interventions, with the explicit aim of reducing the DUI and consequently the treatment gap and its 
damaging effects on mental wellbeing.  As OCD is an illness with its onset in childhood and early to 
middle adulthood, there are strong arguments for targeting such interventions in child and adolescent 
mental health services, services covering the ‘transitional’ phase between childhood and adulthood and 
maternity services.  
 
As many at risk individuals will not turn out to develop OCD, and we do not as yet have reliable outcome 
predictors to determine who will, it is proper to consider the potential harms of early intervention in the 
prodromal stages. For example, undue emphasis may be placed on dysfunctional behaviours that 
spontaneously remit. These ‘false positive’ findings may cause unnecessary anxiety or distress, especially 
for parents of at risk children, and may even lead to unnecessary interventions in some cases. These 
harms are not specific to OCD, relating to early interventions for many other conditions associated with 
a disease burden, and need to be balanced against known harms related to missing the diagnosis. Based 
on evidence presented in this review, we believe that careful monitoring of ultra-high risk cases of OCD 
is reasonable, not only because of the increased risk of developing OCD, but also because cases with a 
family history of OCD may have a six times lower response to CBT (Garcia et al., 2010) and so need to be 
identified early and treated appropriately. We would therefore argue that an early intervention model 
for OCD, with the level of intervention matched to the stage of illness, aligns with the precautionary 
principle guiding public health organizations’ recommendations and actions, requiring that "… scientific 
uncertainty should not be used as a reason to postpone preventive measures" (World Health 
Organization, 2018).  
 
Limitations 
This consensus statement is not a systematic review. Systematic reviews come with their own 
weaknesses e.g. bias driven by the selection of search strategy chosen by the authors, and therefore do 
not represent a flawless process. We believe a narrative review is best suited for the purpose of such 
newly explored ground.  We acknowledge there is as yet little or no prospective evidence that early 
intervention will actually result in better outcomes. Nevertheless, the consensus opinion of this global 
group of experts, derived from this narrative review, is that early intervention based on validated 
staging models, yet to be fully defined, represents the way forward.  
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